Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice

Atypical antipsychotic (AA) medications including risperidone (RIS) and olanzapine (OLAN) are FDA approved for the treatment of psychiatric disorders including schizophrenia, bipolar disorder and depression. Clinical side effects of AA medications include obesity, insulin resistance, dyslipidemia, h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res
Main Authors: Beauchemin, Megan, Geguchadze, Ramaz, Guntur, Anyonya R., Nevola, Kathleen, Le, Phuong T., Barlow, Deborah, Rue, Megan, Vary, Calvin P.H., Lary, Christine W., Motyl, Katherine J., Houseknecht, Karen L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060507/
https://ncbi.nlm.nih.gov/pubmed/31874253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2019.104589
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados